Cargando…

Reasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis: a patient perspective

OBJECTIVE: To examine reasons why rheumatoid arthritis patients discontinued subcutaneous (SQ) anti-tumor necrosis factor (anti-TNF) treatment in the past 12 months, so as to help inform successful, uninterrupted therapy. METHODS: Data were collected in March and April 2011 using self-reported, inte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bolge, Susan C, Goren, Amir, Tandon, Neeta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309782/ https://www.ncbi.nlm.nih.gov/pubmed/25653505 http://dx.doi.org/10.2147/PPA.S70834

Ejemplares similares

Openness to and preference for attributes of biologic therapy prior to initiation among patients with rheumatoid arthritis: patient and rheumatologist perspectives and implications for decision making
por: Bolge, Susan C, et al.
Publicado: (2016)

Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis—the ANSWER cohort study
por: Ebina, Kosuke, et al.
Publicado: (2019)

Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study-
por: Ebina, Kosuke, et al.
Publicado: (2018)

Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study-
por: Ebina, Kosuke, et al.
Publicado: (2019)

Correction to: Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis—the ANSWER cohort study
por: Ebina, Kosuke, et al.
Publicado: (2019)

Patient experience with intravenous biologic therapies for ankylosing spondylitis, Crohn’s disease, psoriatic arthritis, psoriasis, rheumatoid arthritis, and ulcerative colitis
por: Bolge, Susan C, et al.
Publicado: (2017)

Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry
por: Strand, Vibeke, et al.
Publicado: (2017)

Generation-Dependent Retention Rates and Reasons for Discontinuation of Molecular Targeted Therapies in Patients with Rheumatoid Arthritis: From FIRST Registry
por: Kubo, Satoshi, et al.
Publicado: (2023)

Subcutaneous abatacept for the treatment of rheumatoid arthritis
por: Schiff, Michael
Publicado: (2013)

Assessment of Rheumatoid Arthritis Quality Process Measures and Associated Costs
por: Brady, Brenna L., et al.
Publicado: (2017)

Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective
por: Keyser, Filip De
Publicado: (2011)

Comparison of Biologic Discontinuation in Patients With Elderly‐Onset Versus Younger‐Onset Rheumatoid Arthritis
por: Richter, Michael D., et al.
Publicado: (2019)

Reasons for discontinuation of radiation therapy and effective countermeasures
por: Maebayashi, Toshiya, et al.
Publicado: (2018)

Overtreatment in rheumatoid arthritis: are there reasons for concern?
por: Ferreira, Ricardo J O, et al.
Publicado: (2022)

Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians
por: Chen, Jian, et al.
Publicado: (2011)

Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
por: Bhushan, Vandana, et al.
Publicado: (2021)

Patient’s experience with subcutaneous and oral methotrexate for the treatment of rheumatoid arthritis
por: Curtis, J. R., et al.
Publicado: (2016)

Every reason to discontinue lithium
por: Salgado, Manuel E Fuentes, et al.
Publicado: (2014)

Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis
por: van Vollenhoven, Ronald F, et al.
Publicado: (2016)

The Effect of Discontinuing Denosumab in Patients With Rheumatoid Arthritis Treated With Glucocorticoids
por: Saag, Kenneth G., et al.
Publicado: (2022)

Tapering and discontinuation of glucocorticoids in patients with rheumatoid arthritis treated with tofacitinib
por: Spinelli, Francesca Romana, et al.
Publicado: (2023)

Discontinuation rates of biologics in patients with rheumatoid arthritis: are TNF inhibitors different from non-TNF inhibitors?
por: Ramiro, Sofia, et al.
Publicado: (2015)

Prediction of disease flare by biomarkers after discontinuing biologics in patients with rheumatoid arthritis achieving stringent remission
por: Kameda, Hideto, et al.
Publicado: (2021)

Switching and Discontinuation Pattern of Biologic Disease-Modifying Antirheumatic Drugs and Tofacitinib for Patients With Rheumatoid Arthritis in Taiwan
por: Li, Ko-Jen, et al.
Publicado: (2021)

Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy
por: Barton, Jennifer L
Publicado: (2009)

Clinical course of patients with rheumatoid arthritis who continue or discontinue biologic therapy after hospitalization for infection: a retrospective observational study
por: Kashiwado, Yusuke, et al.
Publicado: (2022)

Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous Tocilizumab
por: Negoescu, Andra F., et al.
Publicado: (2014)

Biologic monotherapy in the treatment of rheumatoid arthritis
por: Detert, Jacqueline, et al.
Publicado: (2015)

PM381. Reason for clozapine discontinuation
por: Cho, Jin-Woo, et al.
Publicado: (2016)

Treatment with Biologicals in Rheumatoid Arthritis: An Overview
por: Rein, Philipp, et al.
Publicado: (2017)

Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis
por: Tanaka, Yoshiya, et al.
Publicado: (2020)

Dual Biologic Therapy in Patients with Rheumatoid Arthritis and Psoriatic Arthritis
por: Furer, Victoria, et al.
Publicado: (2023)

Usability and Acceptability of the Abatacept Pre-Filled Autoinjector for the Subcutaneous Treatment of Rheumatoid Arthritis
por: Schiff, Michael, et al.
Publicado: (2016)

Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician
por: Findeisen, Kate E, et al.
Publicado: (2021)

Why do patients discontinue fertility treatment? A systematic review of reasons and predictors of discontinuation in fertility treatment
por: Gameiro, S., et al.
Publicado: (2012)

Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis
por: Suzuki, Takako, et al.
Publicado: (2017)

Duration of natalizumab therapy and reasons for discontinuation in a multiple sclerosis population
por: Conway, Devon S, et al.
Publicado: (2020)

Pharmacoeconomic evaluation of costs of rheumatoid arthritis therapy with selected biological treatment
por: Kowalik, Krzysztof, et al.
Publicado: (2018)

Adherence and persistence of subcutaneous biologics delivered through homecare services to a cohort of patients with rheumatoid arthritis
por: Alvarez-Madrazo, Samantha, et al.
Publicado: (2017)

Methotrexate Discontinuation and Dose Decreases After Therapy With Tocilizumab: Results From the Corrona Rheumatoid Arthritis Registry
por: Pappas, Dimitrios A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cmuvm638e38gcms4bkmvr55jov